**Core Concept**
Malignant hyperthermia is a rare, life-threatening medical emergency that occurs in response to certain anesthetic agents, particularly volatile anesthetics and succinylcholine. It is characterized by a hypermetabolic state in skeletal muscle, leading to excessive heat production, muscle rigidity, and potentially fatal complications.

**Why the Correct Answer is Right**
Malignant hyperthermia is caused by an abnormality in the ryanodine receptor type 1 (RyR1), which is a calcium channel on skeletal muscle cells. When exposed to triggering anesthetics, individuals with this genetic defect experience a massive release of calcium ions, leading to muscle hypermetabolism, increased heat production, and muscle rigidity. This hypermetabolic state is a result of the excessive energy expenditure by the affected muscle cells.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because malignant hyperthermia is a hypermetabolic, not hypometabolic, condition. The affected muscle cells exhibit increased energy expenditure, resulting in excessive heat production.
**Option C:** This option is incorrect because malignant hyperthermia is not a preoperative complication, but rather a perioperative emergency that can occur during or immediately after anesthesia is administered.
**Option D:** This option is incorrect because malignant hyperthermia is inherited in an autosomal dominant, not autosomal recessive, pattern. This means that a single copy of the mutated gene is sufficient to increase the risk of developing the condition.

**Clinical Pearl / High-Yield Fact**
Malignant hyperthermia is often triggered by specific anesthetic agents, and early recognition of symptoms is crucial for timely intervention. The diagnosis is typically made based on clinical presentation, and treatment involves immediate cessation of the triggering agent, administration of dantrolene, and supportive care.

**✓ Correct Answer: B. It is genetic, hypermetabolic muscle disease**